MedPath

Evaluation of Quality of Care - Multi-disciplinary Risk Assessment and Management Programme for Patients With Hypertension, HA (QoC RAMP-HT)

Completed
Conditions
Hypertension
Registration Number
NCT02219958
Lead Sponsor
The University of Hong Kong
Brief Summary

Hypertension (HT) is one of the major cause of morbidity and among the top 10 causes of deaths in Hong Kong in 2008 (Department of Health 2009). The Hospital Authority (HA) has initiated service improvement through introducing the risk assessment and management programme (RAMP) to improve the quality of care (QOC) for HT patients in general outpatient clinics (GOPC). The evaluation on the QOC is an essential part of the programme in order to inform future policy. The Department of Family Medicine and Primary Care (FMPC) of the University of Hong Kong (HKU) has been appointed by the HA to carry out the evaluation of the QOC of the programme.

The Action Learning and Audit Spiral methodologies to measure whether the target standard of care intended by the RAMP programme is achieved. Each RAMP participating clinic and hospital will be invited to complete a structured evaluation questionnaire. The data of all patients who have enrolled into the RAMP for more than one year will be included in the evaluation on the process and outcomes of care.

One thousand two hundred and forty-eight age and disease matched control patients who have not been enrolled into the RAMP programme will be selected for the comparison in the outcomes of care. A hundred and thirty participants will be followed up by telephone to evaluate the effect of the programme in quality of life (QOL), patient enablement, and global rating of change in health condition at baseline and 6 months after enrolment. Data on the process of care will be retrieved from the HA medical records.

Main Outcome Measures: The primary outcomes are the proportion of participants who have received the criterion process of care, and achieved the target blood pressure levels.

Data Analysis: Descriptive statistics on proportions of centers or subjects meeting the QOC criteria will be calculated. The changes in the clinical and patient reported outcomes of RAMP subjects will be compared at 12, 24, 36 and 48 months will be compared by paired sample t-test. The clinical outcomes between RAMP subjects and control group will be compared by independent sample t-test or Chi-square test.

Results: The QOC of the RAMP programme will be determined. Areas of deficiency and possible areas for quality enhancement will be identified.

Conclusion: The results of this study will provide empirical evidence on whether the HA's RAMP programme can achieve improvement in QOC for HT patients. The information will be used to guide service planning and policy decision making.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
2496
Inclusion Criteria
  • HT
  • aged <80
  • Suboptimal BP control (average systolic blood pressure (SBP) ≥ 140mmHg or average diastolic blood pressure (DBP) ≥ 90mmHg)
Exclusion Criteria
  • Patients will be excluded if they are unable to understand or communicate in Chinese language, or refuse to give consent.
  • Patients will be excluded if they had prior history of diabetes and existing cardiovascular diseases

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
The proportion of patients who have complied with the criterion process of care.Three years

Final analysis will evaluate the period from August, 2012 to December, 2014.

The proportion of patients who have achieved a BP level <140/90mmHg.Three years

Final analysis will evaluate the period from August, 2012 to December, 2014.

The proportion of clinics that have satisfied each of the structure criteriaThree years

Final analysis will evaluate the period from August, 2012 to December, 2014.

Secondary Outcome Measures
NameTimeMethod
Occurrence of First Cardiovascular ComplicationThree years

Baseline and 12 months for each subject; the audit cycle will be repeated annually over a period of 3 years.

BMI (Body Mass Index)Three years

Baseline and 12 months for each subject; the audit cycle will be repeated annually over a period of 3 years.

The change in SF-12v2 scoresThree years

Baseline and 6-month/12-month/24-month/36-month after the first administration of questionnaire.

PEI (Patient Enablement Index)Three years

6-month/12-month/24-month/36-month after the first administration of questionnaire.

GRS (Global Rating of Change Scale) scoresThree years

6-month/12-month/24-month/36-month after the first administration of questionnaire.

LDLThree years

Baseline and 12 months for each subject; the audit cycle will be repeated annually over a period of 3 years.

Trial Locations

Locations (1)

The University of Hong Kong

🇭🇰

Hong Kong Island, Hong Kong

© Copyright 2025. All Rights Reserved by MedPath